Commodore Capital LP 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Commodore Capital LP disclosed 31 US equity positions worth $1.4bn in its Q4 2024 13F filing. The largest position was MERUS N V at 11.9% of the reported book, followed by PCVX and NUVALENT INC. Against the Q3 2024 filing, it opened 4 new positions, added to 10 and reduced 8 among the top 31 holdings.
What did Commodore Capital LP own in Q4 2024? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | MERUS N V | 11.9% | $162.9m | 3,874,182 | 16% | added | |
| 2 | PCVX VAXCYTE INC | Healthcare | 9.7% | $133.0m | 1,625,000 | 77% | added |
| 3 | NUVALENT INC | 9.3% | $126.9m | 1,621,600 | 73% | added | |
| 4 | XENE XENON PHARMACEUTICALS INC | Healthcare | 7.9% | $107.4m | 2,740,000 | 1% | added |
| 5 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.9% | $94.6m | 4,205,000 | 3% | added |
| 6 | VERA VERA THERAPEUTICS INC | Healthcare | 6.1% | $82.8m | 1,958,600 | -21% | reduced |
| 7 | SLNOEUR SOLENO THERAPEUTICS INC | 5.0% | $68.5m | 1,525,000 | 21% | added | |
| 8 | ALKS ALKERMES PLC | Healthcare | 4.8% | $66.1m | 2,300,000 | -21% | reduced |
| 9 | NRIX NURIX THERAPEUTICS INC | Healthcare | 4.1% | $56.5m | 3,000,000 | 82% | added |
| 10 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.9% | $53.7m | 6,881,629 | -9% | reduced |
| 11 | SYRE SPYRE THERAPEUTICS INC | 3.4% | $46.3m | 1,988,084 | 0% | held | |
| 12 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 3.4% | $46.0m | 2,400,000 | -6% | reduced |
| 13 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 3.0% | $41.1m | 950,000 | – | new |
| 14 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.7% | $37.2m | 2,218,425 | 64% | added | |
| 15 | PHVS PHARVARIS N V | 2.7% | $36.6m | 1,911,433 | 0% | held | |
| 16 | BRD1EUR MIND MEDICINE MINDMED INC | 2.2% | $30.0m | 4,308,425 | -46% | reduced | |
| 17 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.0% | $27.5m | 1,419,714 | 4% | added |
| 18 | CRDF CARDIFF ONCOLOGY INC | 1.7% | $23.4m | 5,384,616 | – | new | |
| 19 | IKT INHIBIKASE THERAPEUTICS INC | 1.4% | $19.3m | 5,925,000 | – | new | |
| 20 | NGNE NEUROGENE INC | 1.3% | $18.3m | 800,000 | 300% | added | |
| 21 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 1.3% | $18.0m | 500,000 | – | new |
| 22 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.2% | $16.1m | 2,000,000 | 0% | held |
| 23 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.0% | $13.1m | 290,000 | 0% | held |
| 24 | ABVX ABIVAX SA | 0.7% | $9.4m | 1,284,110 | 0% | held | |
| 25 | PERCEPTIVE CAP SOLUTIONS COR | 0.6% | $7.6m | 750,000 | 0% | held | |
| 26 | HELIX ACQUISITION CORP II | 0.4% | $5.2m | 500,000 | 0% | held | |
| 27 | CELC CELCUITY INC | Healthcare | 0.4% | $5.2m | 400,000 | -74% | reduced |
| 28 | VTGN VISTAGEN THERAPEUTICS INC | 0.3% | $4.6m | 1,575,000 | 0% | held | |
| 29 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.3% | $3.6m | 483,000 | 0% | held |
| 30 | THIRD HARMONIC BIO INC | 0.2% | $2.4m | 237,704 | -83% | reduced | |
| 31 | NKTX NKARTA INC | Healthcare | 0.1% | $876.1k | 351,848 | -92% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.